What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China

OBJECTIVE: This study assessed the real-world application, effectiveness, and safety of olaparib and niraparib as maintenance therapies in patients with platinum-sensitive recurrent ovarian cancer (PSROC) in China and investigated clinical factors associated with prolonged benefits of poly ADP-ribos...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Depu, Li, Shuo, Zhang, Xinxin, Peng, Jingwei, Zhang, Shiqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433773/
https://www.ncbi.nlm.nih.gov/pubmed/36059631
http://dx.doi.org/10.3389/fonc.2022.955124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433773/
https://www.ncbi.nlm.nih.gov/pubmed/36059631
http://dx.doi.org/10.3389/fonc.2022.955124

Ejemplares similares